Currently, there are 167.39M common shares owned by the public and among those 140.07M shares have been available to trade.
The company’s stock has a 5-day price change of -24.61% and 8.69% over the past three months. ENVX shares are trading -15.10% year to date (YTD), with the 12-month market performance down to -40.38% lower. It has a 12-month low price of $5.70 and touched a high of $18.68 over the same period. ENVX has an average intraday trading volume of 6.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.37%, -22.80%, and -2.20% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Enovix Corporation (NASDAQ: ENVX) shares accounts for 48.71% of the company’s 167.39M shares outstanding.
It has a market capitalization of $1.81B and a beta (3y monthly) value of 2.11. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.79% over the week and 8.53% over the month.
Analysts forecast that Enovix Corporation (ENVX) will achieve an EPS of -0.21 for the current quarter, -0.2 for the next quarter and -0.73 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.25 while analysts give the company a high EPS estimate of -0.25. Comparatively, EPS for the current quarter was -0.19 a year ago. Earnings per share for the fiscal year are expected to decrease by -0.92%, and 13.21% over the next financial year.
Looking at the support for the ENVX, a number of firms have released research notes about the stock. The Benchmark Company stated their Buy rating for the stock in a research note on July 22, 2024, with the firm’s price target at $25. TD Cowen was of a view on July 21, 2023 that the stock is Market Perform, while Canaccord Genuity gave the stock Buy rating on January 11, 2023, issuing a price target of $20. B. Riley Securities on their part issued Buy rating on December 02, 2022.
